Aug 28, 2018 · HMaxi-K has been tested in two phase 1 studies, including as an injection directly to the bladder in women with OAB symptoms. The latter study, a phase 1b trial, involved 13 patients and found
This study is a double-blind, placebo controlled, parallel design, Phase 2A study evaluating the potential activity and safety of a single administration of hMaxi-K (8000 or 16000 g) or placebo (PBS sucrose 20%) injected into the corpus cavernosum of the penis in men who have been unable to tolerate, do not wish to continue, or have had unsuccessful results with, prior therapy for ED. Urovant licenses overactive bladder gene therapy hMaxi-K Aug 29, 2018 About Urovant | Urovant Sciences Urovant Sciences is a global biopharmaceutical company focused on developing therapies for urologic conditions. Urovant's lead candidate vibegron (RVT-901).
Oct. 25, 2004 — A single subtherapeutic intracavernous injection of the human recombinant Maxi-K ion channel gene via a "naked DNA" plasmid vector (hMaxi-K) is safe in men with moderate to severe
URO 902 is a plasmid vector (hMaxi-K) gene therapy that is in development with Urovant Sciences (a subsidiary of Sumitovant Biopharma), under a license from Ion Evaluating the safety and potential activity of URO‐902 (hMaxi‐K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic Jan 16, 2020 · Evaluating the safety and potential activity of URO‐902 (hMaxi‐K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non‐neurogenic) overactive bladder syndrome and detrusor overactivity from two double‐blind, imbalanced, placebo‐controlled randomized phase 1 trials May 24, 2019 · Abstract. Eleven patients with moderate to severe erectile dysfunction (ED) were given a single-dose corpus cavernosum injection of hMaxi-K, a “naked” DNA plasmid carrying the human cDNA encoding hSlo (for human slow-poke), the gene for the alpha, or pore-forming, subunit of the human smooth muscle Maxi-K channel.
Urovant Sciences is a global biopharmaceutical company focused on developing therapies for urologic conditions. Urovant's lead candidate vibegron (RVT-901).
Uro Pipeline: First patients treated in phase II study of Ion Channel Innovations completed the phase Ib study in 2017 and found hMaxi-K to be generally well tolerated. Clinical results of the trial, which included a limited number of patients (n=13), indicated dose-dependent improvements in urinary urgency and frequency, achieving statistical significance (p<.05) in the high-dose cohort. Phase 1 Study With OAB Assessing the Safety and Activity